Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note issued to investors on Thursday morning. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Trading Up 0.3 %

BTX stock opened at $6.42 on Thursday. The company’s 50-day moving average price is $6.33 and its 200 day moving average price is $2.74. Brooklyn ImmunoTherapeutics has a 52 week low of $5.10 and a 52 week high of $8.31. The company has a market cap of $377.66 million, a P/E ratio of -2.83 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Dividend Announcement

The company also recently disclosed a monthly dividend, which was paid on Monday, March 31st. Investors of record on Friday, March 14th were paid a $0.0862 dividend. This represents a $1.03 annualized dividend and a yield of 16.10%. The ex-dividend date was Friday, March 14th. Brooklyn ImmunoTherapeutics’s payout ratio is currently -44.05%.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.